Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
Emily K. Kleczko, Anh T. Le, Trista K. Hinz, Teresa T. Nguyen, Andre Navarro, Cheng‐Jun Hu, Ana M. Selman, Eric T. Clambey, Daniel T. Merrick, Sizhao Lu, Mary C. Weiser-Evans, Raphael A. Nemenoff, Lynn E. Heasley
Topics & Concepts
OsimertinibGefitinibCancer researchLung cancerAdenocarcinomaMedicineImmunotherapyImmune systemBiologyImmunologyCancerEpidermal growth factor receptorPathologyInternal medicineROS1Lung Cancer Treatments and MutationsCancer Mechanisms and TherapyCancer therapeutics and mechanisms